MedTrace Logo

Need-driven Treatment of the Patients With Type 1 Diabetes

NCT07128992 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 125

Last updated 2025-08-19

No results posted yet for this study

Summary

This prospective study evaluates the safety of extending the interval of routine calendar-based follow-up visits from every 12 months to every 24 months in patients with type 1 diabetes who are in good glycemic control and suitable for remote monitoring. The primary outcome is the proportion of patients who maintain good glycemic control during the 24-month follow-up period.

Participants will attend two in-person visits at baseline (month 0) and at the end of follow-up (month 24), which include a comprehensive clinical examination, assessment of glucose control, and laboratory testing. One remote contact will occur at month 12 for prescription renewal and review of glucose data. Patients may contact their care unit as needed throughout the study. At the baseline and final visits, participants will complete a questionnaire assessing their perceived ability to manage self-care, the safety of the care plan, and their ability to contact their care provider when necessary.

Conditions

  • Type 1 Diabetes (T1D)
  • Glucose Control

Interventions

OTHER

Control visit interval

Study investigates whether it is safe to extend the interval of routine calendar-based follow-up visits from every 12 to every 24 months in patients with type 1 diabetes.

Sponsors & Collaborators

  • Tampere University Hospital

    lead OTHER

Principal Investigators

  • Saara Metso, MD, PhD · Tampere University Hospital, Pirkanmaa Wellbeing County

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-06
Primary Completion
2028-12-31
Completion
2028-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07128992 on ClinicalTrials.gov